WuXi Biologics Launches First Commercial Pharmaceutical Facility for Prefilled Syringes

  • WuXi Biologics provides global partners with high-efficiency, high-quality manufacturing services for clinical trials and commercial supply by increasing pre-filled syringe (PFS) capacity to 17 million units per year.
  • WuXi Biologics has established a global manufacturing network with 9 vial and PFS pharmaceutical facilities in China and Germanyand is today one of the world leaders in CDMO services for pharmaceutical products.
  • Advanced single-use technology and automated equipment help reduce the risk of contamination.

WUXI, China, June 5, 2022 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), an RDCMO global services company, announced that it has successfully launched GMP operation of its new DP5 pharmaceuticals facility located in Wuxi, China. DP5 is the ninth operational pharmaceutical facility in WuXi Biologics’ global network.

The DP5 facility features an advanced isolator fill line for continuous and regular filling services, which offers multiple volume delivery options for pre-filled syringes (PFS), including 1ml long, 1ml, 2 ,25ml and 3ml. The maximum filling speed can reach 400 PFS/min to support the manufacturing of 17 million medicine syringes every year. The increased manufacturing capacity of DP5 enables WuXi Biologics to provide global partners with faster and more robust end-to-end pharmaceutical services for their innovative products at various scales and stages.

Compared to a traditional pharmaceutical filling line, DP5’s state-of-the-art design and layout, single-use technology and automated equipment significantly reduce the risk of contamination and maintain the aseptic control required in the filling process. This process supports customer products to marketability and reliably delivers them to patients at the highest quality standards that WuXi Biologics represents.

dr. Chris ChenCEO of WuXi Biologics, said, “Prefilled syringes have become one of the fastest growing choices for biologics dosage forms as our partners search for new, more convenient methods of biologics administration. The GMP operation of DP5, our first commercial drug for prefilled syringes, not only demonstrates our commitment to our global partners, but also marks an important milestone for WuXi Biologics to become one of the world leaders in pharmaceutical CDMO services. We will continue to enable our customers to advance innovative biologics through clinical trials, regulatory approvals and commercialization to benefit patients around the world. »

About WuXi Biologics

WuXi Biologics (2269.HK) is a global contract research, development and manufacturing organization (CRDMO) providing end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 10,000 skilled employees in China, United States, Ireland, Germanyand Singapore, WuXi Biologics leverages its technologies and expertise to provide its customers with efficient and cost-effective solutions for the discovery, development and manufacturing of biologics. As of the end of 2021, WuXi Biologics is supporting more than 480 integrated customer projects, including nine in commercial manufacturing.

WuXi Biologics views environmental, social and governance (ESG) responsibilities as an integral part of our business philosophy and strategy, and we aim to become an ESG leader in the CRDMO biologics industry. Our facilities use next-generation biomanufacturing technologies and clean energy sources. We have also set up an ESG committee led by our CEO to drive the overall ESG strategy and its implementation, reinforcing our commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.


[email protected]

[email protected]

SOURCE WuXi Biologics


Comments are closed.